180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 34.9% in November

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 90,800 shares, a decrease of 34.9% from the October 31st total of 139,400 shares. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 18.5% of the company’s stock are short sold.

180 Life Sciences Stock Performance

ATNF traded up $0.04 during trading on Friday, hitting $2.23. 34,643 shares of the company’s stock traded hands, compared to its average volume of 770,433. The company’s 50 day simple moving average is $2.73 and its two-hundred day simple moving average is $2.16. 180 Life Sciences has a 12-month low of $1.16 and a 12-month high of $17.75.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.